- Home
- NFBK vs TERN Comparison
NFBK vs TERN Comparison
Compare NFBK & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- TERN
- Stock Information
- Founded
- NFBK 1887
- TERN 2017
- Country
- NFBK United States
- TERN United States
- Employees
- NFBK N/A
- TERN N/A
- Industry
- NFBK Major Banks
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- TERN Health Care
- Exchange
- NFBK Nasdaq
- TERN Nasdaq
- Market Cap
- NFBK 482.5M
- TERN 531.9M
- IPO Year
- NFBK 2007
- TERN 2021
- Fundamental
- Price
- NFBK $10.88
- TERN $6.05
- Analyst Decision
- NFBK Buy
- TERN Buy
- Analyst Count
- NFBK 2
- TERN 5
- Target Price
- NFBK $13.00
- TERN $15.63
- AVG Volume (30 Days)
- NFBK 174.5K
- TERN 994.5K
- Earning Date
- NFBK 07-23-2025
- TERN 08-04-2025
- Dividend Yield
- NFBK 4.78%
- TERN N/A
- EPS Growth
- NFBK 28.89
- TERN N/A
- EPS
- NFBK 0.86
- TERN N/A
- Revenue
- NFBK $133,079,000.00
- TERN N/A
- Revenue This Year
- NFBK $8.33
- TERN N/A
- Revenue Next Year
- NFBK $15.77
- TERN N/A
- P/E Ratio
- NFBK $12.62
- TERN N/A
- Revenue Growth
- NFBK 4.86
- TERN N/A
- 52 Week Low
- NFBK $9.40
- TERN $1.87
- 52 Week High
- NFBK $14.39
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- NFBK 33.02
- TERN 79.93
- Support Level
- NFBK $11.18
- TERN $5.54
- Resistance Level
- NFBK $11.57
- TERN $6.21
- Average True Range (ATR)
- NFBK 0.27
- TERN 0.30
- MACD
- NFBK -0.08
- TERN 0.09
- Stochastic Oscillator
- NFBK 2.94
- TERN 92.92
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.